CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma

Clinical trial NCT05212584 · UNKNOWN

Trial details

NCT number: NCT05212584
Sponsor: iCell Gene Therapeutics
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed/Refractory, High Risk Hematologic Malignancies T-ALL/Lymphoma

Start date: 2022-07-01
Primary completion: 2024-06-30
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.